GlassScriptPhysician profile
Kristin M Grunbaum
NPI 1114110228
$4,127.80
in general payments reported to CMS, 2019-2025
37 companies · $2,264 in 2025
The $2,264 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $367 · 2023: $317 · 2024: $938 · 2025: $2,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,422 · Education: $96.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,422.05 |
| Education | $96.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $518.12 | 2021-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $511.87 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $450.03 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $311.83 | 2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.71 | 2021-2025 | Ofev, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $251.10 | 2024-2025 | Glassia, Hyqvia |
| Amgen INC. | $215.25 | 2022-2025 | Tezspire |
| Insmed, INC. | $177.40 | 2024-2025 | Arikayce, Brinsupri |
| Pfizer INC. | $147.67 | 2021-2025 | |
| Kaleo, INC. | $121.25 | 2021-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $97.10 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $93.70 | 2025 | Nuzyra, Xhance |
| Electromed, INC. | $89.78 | 2025 | Smartvest |
| Csl Behring | $79.64 | 2025 | Hizentra |
| Merck Sharp & Dohme LLC | $79.16 | 2025 | Winrevair, Capvaxive |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $75.56 | 2025 | Prolastin-C Liquid |
| Optinose US, INC. | $61.32 | 2021-2025 | |
| United Therapeutics Corporation | $56.10 | 2024-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $50.49 | 2024-2025 | |
| Baxter Healthcare | $46.64 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Ars Pharmaceuticals Operations, INC. | $42.39 | 2025 | Neffy |
| Octapharma USA, INC. | $38.07 | 2024-2025 | Panzyga |
| Mallinckrodt Hospital Products INC. | $35.60 | 2025 | Acthar |
| Greer Laboratories, INC. | $31.88 | 2025 | Oralair |
| Pharming Healthcare, INC. | $26.93 | 2023 | Ruconest |
| Genzyme Corporation | $24.18 | 2022 | |
| Philips North America LLC | $23.90 | 2024 | (Ak6) Vest Therapy |
| Gc Biopharma USA, INC. | $22.72 | 2025 | Alyglo |
| Viatris Specialty LLC | $22.65 | 2025 | Yupelri |
| Alk-Abello, INC | $22.64 | 2021 | |
| Genentech USA, INC. | $22.07 | 2021 | |
| Phadia US INC. | $21.47 | 2023 | Immunocap |
| Verona Pharma, INC. | $20.71 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $20.50 | 2021 | |
| Biocryst US Sales Co., LLC | $20.05 | 2022 | |
| Incyte Corporation | $18.31 | 2022 | |
| Lilly USA, LLC | $18.01 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Grunbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.